Hengrui Therapeutics, Inc.
Also known as: Guangdong Hengrui Pharmaceutical Co., Ltd | HENGRUI PHARMA | HengRui YuanZheng Bio-Technology Co.,Ltd. | JIANGSU HENGRUI MED | Jiangsu HengRui Medicine Co. | Jiangsu HengRui Medicine Co., Ltd. | Jiangsu Hengrui Pharmaceutical Co., Ltd. | Jiangsu Hengrui Pharmaceutical Co., LTD | Jiangsu Hengrui Pharmaceuticals Co.,Ltd | JIANGSU HENGRUI PHARMACEUTICALS CO LTD | SHANGHAI HENGRUI | Shanghai Hengrui Pharmaceutical Co., Ltd. | Yue Han | Zhigang Li
Highest phase reached
Phase 4
Timeline
1970s
- Jan 1, 1970
Hengrui Therapeutics, Inc.— Founded
2010s
- Dec 16, 2011
irinotecan— Marketing Organization
Drugs by trial phase (280 distinct, 840 trials)
Phase 4 (13 own, 0 via acquisition)
Phase 3 (102 own, 0 via acquisition)
Phase 2 (99 own, 0 via acquisition)
Phase 1 (64 own, 0 via acquisition)
Other trials (2 own, 0 via acquisition)
Indications
Studied for
- Adenocarcinoma
- Adenocarcinoma of Lung
- Agnosia
- Anemia
- Anemia, Aplastic
- Arthritis
- Arthritis, Rheumatoid
- Biliary Tract Neoplasms
- Brain Neoplasms
- Breast Neoplasms
- Bronchial Neoplasms
- Carcinoma
- Carcinoma, Bronchogenic
- Carcinoma, Hepatocellular
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Renal Cell
- Carcinoma, Squamous Cell
- Carcinoma, Transitional Cell
- Cholangiocarcinoma
- Colorectal Neoplasms
- Depression
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Digestive System Diseases
- Digestive System Neoplasms
- Disease Progression
- Endometrial Neoplasms
- Endometriosis
- Esophageal Diseases
- Esophageal Neoplasms
- Esophageal Squamous Cell Carcinoma
- Essential Hypertension
- Fallopian Tube Neoplasms
- Febrile Neutropenia
- Fibromyalgia
- Gastrointestinal Diseases
- Gastrointestinal Neoplasms
- Gastrointestinal Stromal Tumors
- Glioblastoma
- Glioma
- Gout
- Heart Failure
- Heart Failure, Systolic
- Hematologic Neoplasms
- Hepatitis
- Hepatitis A
- Hepatitis B
- Hepatitis B, Chronic
- Hepatitis, Chronic
- Hernia
- Hernia, Inguinal
- Hodgkin Disease
- Hypercholesterolemia
- Hyperlipidemias
- Hyperlipoproteinemias
- Hyperlipoproteinemia Type II
- Hypersensitivity
- Hypertension
- Hypertriglyceridemia
- Hyperuricemia
- Hyponatremia
- Intestinal Neoplasms
- Kidney Diseases
- Leukemia
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Liver Diseases
- Liver Neoplasms
- Lung Diseases
- Lung Neoplasms
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Extranodal NK-T-Cell
- Lymphoma, T-Cell
- Melanoma
- Myelodysplastic Syndromes
- Myofascial Pain Syndromes
- Nasopharyngeal Carcinoma
- Nasopharyngeal Neoplasms
- Neoplasm Metastasis
- Neoplasms
- Neoplasms by Histologic Type
- Neoplasms by Site
- Neoplasms, Second Primary
- Neoplasms, Squamous Cell
- Neuralgia
- Neuralgia, Postherpetic
- Neuroendocrine Tumors
- Neutropenia
- Osteoarthritis
- Osteoarthritis, Knee
- Osteoporosis
- Osteoporosis, Postmenopausal
- Osteosarcoma
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Philadelphia Chromosome
- Preleukemia
Marketed drugs (20)
Recent trials (50)
- NCT07286032Lead sponsorPhase 3Feb 28, 2026
- NCT07289763Lead sponsorPhase 2Jan 31, 2026
- NCT07311694Lead sponsorPhase 3Jan 31, 2026
- NCT07232875Lead sponsorPhase 3Dec 31, 2025
- NCT07309055Lead sponsorPhase 3Dec 31, 2025
- NCT07264335Lead sponsorPhase 1Dec 31, 2025
- NCT07299422Lead sponsorPhase 2Dec 31, 2025
- NCT07268040Lead sponsorPhase 2Dec 31, 2025
- NCT07238283Lead sponsorPhase 3Dec 31, 2025
- NCT07296341Lead sponsorPhase 1/Phase 2Dec 31, 2025
- NCT07241416Lead sponsorPhase 3Dec 31, 2025
- NCT07301333Lead sponsorPhase 1Dec 31, 2025
- NCT07232849Lead sponsorPhase 2Nov 30, 2025
- NCT07229729Lead sponsorPhase 2Nov 30, 2025
- NCT07229716Lead sponsorPhase 1Nov 30, 2025
Details
- Founded
- Lianyungang, CN Jan 1, 1970
- Last known activity
- Feb 28, 2026
Notes
--- Pre-folding founded info: 2016-01-01 Princeton NJ US https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapid=368116889 ---